Wednesday, July 8, 2026

Patent intelligence · US

US 9840549

Fusion polypeptides capable of activating receptors

granted A61PA61P17/02A61P3/10A61P9/10
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 11
Applicant portfolio 837
Patent details — US 9840549
Jurisdiction
US
Status
granted
Grant date
Dec 12, 2017
Expiration
Dec 7, 2037
Claims
30
CPC classes
A61P, A61P17/02, A61P3/10, A61P9/10
View on Google Patents ↗

Quick answer

US 9840549 (Fusion polypeptides capable of activating receptors) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61P, A61P17/02, A61P3/10, A61P9/10

More from REGENERON PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421512

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  2. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  3. US 12421315

    CLL-1 targeted immunotherapies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  4. US 12419963

    Diels-Alder conjugation methods

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  5. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 11, 2045

    granted
  6. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 4, 2045

    granted
  7. US 12404505

    Delivery of a gene-editing system with a single retroviral particle and methods of generation and use

    REGENERON PHARMACEUTICALS, INC. · Expires Aug 28, 2045

    granted
  8. US 12402611

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 9840549?

US 9840549 (Fusion polypeptides capable of activating receptors) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9840549?

REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.

When does US 9840549 expire?

Our index shows an expiration date of Dec 7, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.